Kristen Belmonte Slaoui Husband, Bio, Wiki, Age, Height, Education, Net Worth, Husband Age, COVID-19 Vaccines, GSK and Husband Job

Kristen Belmonte Slaoui Biography

Kristen Belmonte Slaoui is an American citizen famous for being the wife of Moncef Slaoui, an American-Belgian-Moroccan researcher. She is the vice president at GlaxoSmithKline Plc in North America and the assistant professor at The Hopkins Bloomberg.

Kristen Belmonte Slaoui Age and Birthday

Kristen is 50 years old as of 2020, she was born in July 1970 in the United States of America.

Kristen Belmonte Slaoui Height and Weight

Kristen stands at a height of 5 feet 8 inches (1.72 meters) tall. Her weight is not available.

Kristen Belmonte Slaoui Family and Education

Kristen was born and raised by her parents in the United States of America. She has not disclosed any information regarding her family, parents nor her siblings. She attended Gettysburg College where she earned her Bachelor’s degree in both Biology and Classical Studies. She also joined The John Hopkins Bloomberg School of Public Health where she earned her Ph. D in Physiology. Kristen also completed an NIH Post Doctoral Fellowship at the University of Washington in Seattle, WA.

Kristen Belmonte Slaoui Husband Moncef Slaoui

Kristen is married to her husband Moncef Slaoui, who is an American-Belgian-Moroccan researcher. The couple tied the knot in March 2011 at the Lippincott House Bed and Breakfast off of Rittenhouse Square. They are blessed with two children together, a son and a daughter.

Kristen Belmonte Husband Age

Moncef is 61 years as of 2020, he was born on 27 July 1959 in Agadir, Morocco. Moncef celebrates his birthday on 27th July every year. He will be turning 61 years old on 27 July.

Kristen Belmonte Slaoui Net Worth

Kristen has an estimated net worth of over $100,000 as of 2021, She is the vice president at GlaxoSmithKline Plc in North America and the assistant professor at The Hopkins Bloomberg.

Kristen Belmonte Slaoui GSK Wiki

Belmonte is Vice President as well as Head of Business Development for GlaxoSmithKline’s (GSK) Pharmaceuticals Commercial Portfolio. Kristen has spent about 20 years working with GSK.

She first worked in the research labs, where her works mainly in pulmonary disease resulted in the discovery of the long-acting muscarinic receptor antagonist in the approved medicines.

Kristen holds multiple patents. She has as well authored more than 40 original peer-reviewed publications. Kristen has had ongoing roles as a peer reviewer for multiple established journals.

Belmonte has held several roles, more so of increasing seniority since she joined GSK’s Business Development teams in the year 2006. She has well-executed more than  30 million dollars worth of deals and acquisitions.

Kristen accepted a position in Respiratory Drug Discovery at GSK. This was after her team in Seattle. Prior to accepting a position in Respiratory Drug Discovery, Kristen continued her commitment to academic research by spending over a decade as an adjunct assistant professor.

Also Read About: Dr. Vin Gupta MD, Wiki, Bio, Age, Height, Family, Brother, Wife, Married, CNN, Coronavirus, Pulmonologist, Net Worth and Salary

Kristen Belmonte Slaoui Husband COVID-19 Vaccines

As a tide of late-stage data rolls in on COVID-19 vaccines from Pfizer, Moderna, and AstraZeneca, the U.S. is gearing up for reviews that could see a vaccine authorized and deployed before the year is out.

On Saturday, the chief of the White House’s Operation Warp Speed effort laid out a definitive timeline, setting expectations for when the public could expect at least two shots to become available.

Moderna will file for an emergency nod for its mRNA-based vaccine candidate before the month is out, Moncef Slaoui, Ph.D., head of “Warp Speed” and former vaccine chief at GlaxoSmithKline, said during an interview on ABC News’ “This Week with George Stephanopoulos.”

That submission will segue straight into a Dec .17 data review, with the aim to ship vaccines to distributors within 24 hours of approval and potentially start vaccinations two days after the advisory panel makes its call, Slaoui said.

Moderna last Monday revealed it’s shot hopeful, mRNA-1273, posted nearly 95% efficacy in phase 3. Only five COVID-19 cases were reported among those who received the shot, compared with 90 cases including 11 that were severe confirmed in the placebo arm.

Slaoui also touched on hesitancy around an approved COVID shot, not just from the public, but among healthcare workers, doctors, and nurses, which the Warp Speed chief called “unfortunate.”

The vaccines in the works have been developed “as thoroughly and as scientifically as ever,” with speed representing the distinguishing factor in the government’s efforts, he said.

Slaoui cited politics as the key driver of shot skepticism in recent months, adding that, to his knowledge, there had been no intentional effort on Pfizer’s part to delay its data submission until after the election, as President Donald Trump has recently alleged.

Kristen Belmonte Slaoui Husband Moncef Job

Kristen’s husband, Moncef is a professional researcher named together with the general of United States Army Materiel Commander, Gustave F. Perna, to lead Operation Warp Speed, the government’s efforts to speed up the development of the coronavirus vaccine. The two were appointed on May 15, 2020, by President Trump.

Both Moncef and Perna will lead to a crash development program ordered by President Trump.  All this is meant to ensure that a vaccine will be absolutely ready for wide distribution in the United States by early, next year. In late April, officials at the Department of Health and Human Services confirmed the effort but provided few details.

Blogging at
Jimmy Mutua is a well-experienced Author from with good experience in the blogging sector. Giving you the best from true and verified information.
Jimmy Mutua

About Jimmy Mutua

Jimmy Mutua is a well-experienced Author from with good experience in the blogging sector. Giving you the best from true and verified information.

View all posts by Jimmy Mutua →